Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNDX-5613, ASTX727, and Venetoclax in Acute Myeloid Leukemia (SAVE)
NCT05360160Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of revumenib in acute myeloid leukemia (AML) and mixed phenotype acute leukemia (MPAL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Recommended Phase II Dose at 1 year. Started Oct 2022; status: recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT05360160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360160.